Sept 17 (Reuters) - French animal health company Virbac VIRB.PA reported a higher core profit on Thursday, citing strong organic growth.
Virbac said recurring operating profit, excluding amortization of assets due to acquisitions, rose 6.8% to 144.2 million euros ($165.50 million) in the first half of 2026, compared with 135.0 million euros a year earlier.
($1 = 0.8713 euros)
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
